Under construction – not a live service
Sign in
Not yet taking people in ItalyPhase 1

Tests KK2223 in adults with T-cell non-Hodgkin lymphoma

Tests KK2223, a new drug, in adults with T-cell non-Hodgkin lymphoma.

Plain-language title generated from the registry record
Registry title: A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma

Key facts

Where
Bergamo, Bologna, Candiolo, and Turin, ItalySee the 4 sites
Phase
Phase 1

Where in Italy

  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIIIBergamo, ItalyNot yet recruiting
  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere ScientificoBologna, ItalyNot yet recruiting
  • Istituto di Candiolo Fondazione del Piemonte per l'oncologia IRCCSCandiolo, ItalyNot yet recruiting
  • Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di TorinoTurin, ItalyNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Kyowa Kirin Inc.
Trial code
NCT07192471EU 2025-522523-96-00
Record updated
15 October 2026